Helix BioPharma Announces Director Resignations
(firmenpresse) - AURORA, ONTARIO -- (Marketwire) -- 12/17/12 -- Helix BioPharma Corp. (TSX: HBP)(FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced that each of Jack A. Kay and W. Thomas Hodgson had voluntarily resigned from Helix's board of directors with effect from December 14, 2012.
Commenting on the resignations, William White, Chairman of the Board of Helix said, "Jack Kay and Tom Hodgson have been valued members of Helix's board of directors for over seven years and four years, respectively. Over the past eight months in particular, their insight and perspective, and their diligence, has provided vital continuity for the board while it has made several key business and strategic decisions for the company. We regret their departure and wish them both well in the future."
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is currently listed on the TSX and FSE under the symbol "HBP".
Forward-Looking Statements and Risks and Uncertainties
This news release contains certain forward-looking statements and information (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws. Forward-looking statements, which may be identified by words including, without limitation, "will", "anticipate" and other similar expressions, are intended to provide information about management's current plans and expectations regarding future operations.
Although Helix believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties that may cause actual results or events to differ materially from those anticipated and no assurance can be given that these expectations will be realized, and undue reliance should not be placed on such statements. Risk factors that could cause actual results or events to differ materially from the forward-looking statements include, without limitation, those risks described in Helix's most recent Annual Information Form, including under the headings "Forward-Looking Statements" and "Risk Factors", filed with the Canadian Securities Administrators at (together, the "Helix Risk Factors"). Certain material factors or assumptions are applied in making the forward-looking statements, including, without limitation, that the Helix Risk Factors will not cause Helix's actual results or events to differ materially from the forward-looking statements.
Forward-looking statements and information are based on the beliefs, assumptions and expectations of Helix's management on the date of this news release, and Helix does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions or expectations, or other circumstances change, except as required by law.
Contacts:
Helix BioPharma Corp.
Investor Relations
905 841-2300
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 17.12.2012 - 09:35 Uhr
Sprache: Deutsch
News-ID 1180956
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
AURORA, ONTARIO
Phone:
Kategorie:
Alternative
Anmerkungen:
Diese Pressemitteilung wurde bisher 139 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Helix BioPharma Announces Director Resignations
"
steht unter der journalistisch-redaktionellen Verantwortung von
Helix BioPharma Corp. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
